Skip to content
AnalystLens

Charles River Laboratories InternationalCRL

Legal name
Charles River Laboratories International, Inc.
Industry
Services-Commercial Physical & Biological Research
Exchange
NYSE

Stock Price $CRL

Filing record · 2016–202610-K1110-Q338-K118

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 118 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jan ’26Jan ’26
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  1. $4.02B
YoY changeLargest recent move+23.3%in FY16Latest −0.9%

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →

Charles River Laboratories International Financial Overview 2021–2025

Updated Nov 5, 2026

Charles River Laboratories posted a $10.3 milliona net profit in FY2024, down from $474.6 million a year earlier, then swung to a $144.3 million loss in FY2025. Revenue barely moved, so the damage came from write-downs and restructuring, not collapsing demand. The core thesis: this is a stable, cash-generative testing business whose reported earnings are being distorted by acquisition-era mistakes in cell and gene therapy manufacturing.

Revenue grew from $3.54 billion in FY2021 to $4.02 billionb in FY2025, though it peaked at $4.13 billion in FY2023 and has slipped since. Operating margin tells the sharper story: 16.7% in FY2021, 14.9% in FY2023, 5.6% in FY2024 and just 0.6% in FY2025. The FY2024 drop included a $215.0 million goodwill impairment and $107.0 million of restructuring charges. FY2025 added a $165.0 million goodwill impairment in Biologics Solutions. Manufacturing lost $184.3 million at the operating line, while DSA earned $424.6 million on $2.40 billion of revenue.

Cash held up. Operating cash flow reached $737.6 millionc in FY2025, up from $546.6 million in 2020 and above $760.8 million-era levels only marginally lower. Debt and finance leases fell from $2.7 billion in FY2021 to $2.1 billion in FY2025, and the company repurchased $350.0 million of stock in 2025. Management targets about $300 million of cumulative annualized savings by the end of 2026. At the close of FY2025, the shares traded at $203.66, a $10.0 billion market cap, while trailing EPS was -$2.91, so a P/E multiple was not meaningful.

Recent Developments (Q2 and Q3 2026)

CRL's Q3 2026 was the clear inflection. Organic revenue grew 4.7%, even as reported revenue fell 2.2% to $982.7 milliond after the May divestitures of CDMO and Cell Solutions and parts of European Discovery. Non-GAAP operating margin rose 330 basis points to 23.0%, and DSA organic revenue grew 5.9%. GAAP EPS of $6.86 was inflated by a $201 million tax reserve reversal. In Q2 2026, organic growth was only 0.1%. Management raised 2026 non-GAAP EPS guidance to $11.35–$11.55 and, in September, launched "Create the Future" with 2030 targets of 5%–7% organic growth and a roughly 24% margin.

Bull case: demand is improving, margins are expanding, and guidance has risen twice. Bear case: debt rose to $2.46 billione after the $507.3 million Cambodian NHP supplier purchase, and a securities class action over primate imports has no estimable exposure. At $326.29 as of 2026-11-03, the shares trade near 28x the high end of non-GAAP guidance. A GAAP P/E is not meaningful on trailing EPS of -$2.91.

What to watch: whether organic growth holds above 1.5% in Q4 2026; early savings from Create the Future

Recent SEC Filings

  1. 8-KCharles River Laboratories International 8-K Report, Regulation FD Disclosure (Nov 9, 2026)Charles River Laboratories International (CRL) has announced a definitive agreement to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania, for approximately $470 million in cash, plus potential performance-based payments up to $75 million. This strategic acquisition is expected to close in the first half of 2027, subject to customary approvals. The transaction is designed to significantly strengthen CRL's bioanalysis capabilities, particularly in the high-growth clinical bioanalysis sector, and enhance its offering across the entire drug development lifecycle. This move aligns with CRL's "Pathway to Purpose" strategy, aiming to bolster scientific leadership, expand its presence in complex modalities, and improve client continuity from preclinical to clinical testing. The acquired operations include two sites in Exton, PA, approximately 150,000 square feet, and employ around 340 people. Frontage's bioanalysis and DMPK businesses represented about 40% of their total 2025 revenue. CRL anticipates the acquired businesses will grow in line with the projected bioanalysis sector growth. While expected to be neutral to non-GAAP EPS in 2027, the acquisition is projected to be accretive thereafter, with financing to be drawn from the company's credit facility and available cash.
  2. 8-KCharles River Laboratories International 8-K Report, Financial Results (Nov 4, 2026)Charles River Laboratories International, Inc. (NYSE: CRL) reported third-quarter 2026 results for the quarter ended September 26, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K. Third-quarter revenue was $982.7 million, down from $1,004.9 million a year earlier, mainly due to the May 2026 divestitures; on an organic basis revenue rose 4.7%. GAAP earnings per diluted share were $6.86, boosted by a $245.6 million, or $5.06 per share, benefit from the reversal of acquired tax reserves. Non-GAAP diluted EPS was $3.09, up 27.2% from $2.43. The company raised its 2026 guidance. Organic revenue growth is now expected to be at least +1.5% (previously 0.0% to 1.0%), and non-GAAP EPS is now $11.35 to $11.55 (previously $11.15 to $11.45). GAAP EPS guidance rose to $8.15 to $8.35 from $3.05 to $3.35. Management attributed the increase mainly to better-than-expected DSA segment performance and a lower tax rate. Management also highlighted the 2026 Investor Day unveiling of its Pathway to Purpose strategy and Create the Future initiative. Segment results were mixed. DSA revenue was $596.3 million, with organic growth of 5.9% and non-GAAP operating margin of 26.8%. Manufacturing Solutions revenue was $178.9 million, with organic growth of 7.4% and non-GAAP operating margin of 38.6%. Research Models and Services revenue was $207.5 million, with organic revenue down 0.6% and non-GAAP operating margin of 24.4%.
  3. 8-KCharles River Laboratories International 8-K Report, Regulation FD Disclosure (Sep 24, 2026)Charles River Laboratories International, Inc. (NYSE: CRL) furnished a press release dated September 24, 2026, issued in connection with its 2026 Investor Day. The release outlines the company's "Pathway to Purpose" strategy, which rests on three initiatives: modernizing the company to drive productivity and efficiency, strengthening its scientific portfolio, and delivering a customized, client-centric approach. The company expects over $300 million in cumulative savings from its Create the Future™ program from 2027 through 2030, and it expects bioanalysis revenue to grow organically at a high-single-digit CAGR to approximately $450 million in 2030. The company reaffirmed its 2026 financial guidance, last updated on August 5, 2026, and now expects revenue and non-GAAP earnings per share at the upper ends of their prior ranges, primarily reflecting continued favorable demand from biopharmaceutical clients. The 2026 guidance ranges are 0% to 1% organic revenue growth, a non-GAAP operating margin of 21.0% to 21.3%, and non-GAAP EPS of $11.15 to $11.45. For 2030, the company introduced long-term targets of 5% to 7% organic revenue growth (2027-2030 CAGR), a non-GAAP operating margin of approximately 24%, and low-double-digit non-GAAP EPS growth (2027-2030 CAGR). The company states these targets do not include future acquisitions or divestitures, are not projections, and are not financial guidance. The information is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act.
  4. 8-KCharles River Laboratories International 8-K Report, Financial Results (Aug 5, 2026)Charles River Laboratories International, Inc. reported second-quarter 2026 results for the quarter ended June 27, 2026, with revenue of $1.00 billion, down 2.7% from $1.03 billion a year earlier, and organic revenue growth of 0.1%. GAAP results were weaker, with a net loss attributable to common shareholders of $(1.5) million, or $(0.03) per diluted share, compared with net income of $52.3 million, or $1.06 per share, a year earlier. The company attributed the decline mainly to a $63.7 million, or $1.40 per share, loss on the CDMO and Cell Solutions divestiture. On a non-GAAP basis, diluted EPS was $3.02, versus $3.12 in the prior-year quarter, and the non-GAAP operating margin fell to 20.5% from 22.1%, mainly on higher study-related direct costs in the DSA segment. Management cited improving demand, particularly in the DSA segment, where it recorded the highest net book-to-bill in nearly four years. Based on second-quarter performance and improving demand trends, the company raised its 2026 guidance: organic revenue growth is now 0.0% to 1.0% (previously (1.5)% to (0.5)%), and non-GAAP EPS is now $11.15 to $11.45 (previously $10.80 to $11.30). GAAP EPS guidance was lowered to $3.05 to $3.35 from $5.35 to $5.85, primarily because of the divestiture-related net loss. The company also repurchased $100.0 million of stock in the quarter and has $700.0 million remaining under its $1.0 billion authorization. An Investor Day is scheduled for September 24, 2026.
  5. 8-KCharles River Laboratories International 8-K Report, Executive Changes (May 11, 2026)Charles River Laboratories International, Inc. filed this Form 8-K dated May 11, 2026 to report the results of its 2026 annual meeting of shareholders, held May 5, 2026. At the meeting, shareholders approved the company's 2026 Long-Term Incentive Plan, which the Board had adopted on March 11, 2026, subject to shareholder approval. The filing states that the full description of the plan appears in the Proxy Statement filed March 31, 2026, and that the plan itself is attached as Exhibit 10.1. All twelve director nominees were elected to serve until the 2027 annual meeting. Shareholders also approved, on an advisory basis, the compensation of the named executive officers, approved the 2026 Long-Term Incentive Plan, and ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2026. The vote on the auditor ratification was the one proposal where the filing reports zero broker non-votes, and the filing identifies Computershare Trust Company, N.A. as the independent proxy tabulator and inspector of election. For investors, the filing's key takeaways are the shareholder approval of the new incentive plan and the continued election of the full board slate. Vote counts for Abraham Ceesay (35,798,426 for and 8,288,770 against) were noticeably lower in support than those of the other directors, and the filing reports them without further commentary.
View all 8-K filings →